Assignee
CELL and GENE THERAPY Ltd
GB·1 granted patent·7 pending applications·2 citations·filing 2018–2019
Top patents by PatentIndex Score
8 records- 0170US11149279B2Gene therapy DNA vector VTvaf17, method of production; Escherichia coli strain SCS110-AF, method of production; Escherichia coli strain SCS110-AF/VTvaf17 bearing gene therapy DNA vector VTvaf17, method of productionCELL and GENE THERAPY Ltd·Filed 2018·Granted Oct 19, 2021·2 cites·3 claims
- 0241US2024156986A1Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, and PLOD1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, or Escherichia coli strain SCS110-AF/VTvaf17-COL1A2, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA1, or Escherichia coli strain SCS110-AF/VTvaf17-P4HA2, or EschCELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
- 0338US2022119837A1Gene therapy dna vector based on gene therapy dna vector vtvaf17CELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
- 0438US2024307558A1Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB3, and COL7A1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-KRT5, or Escherichia coli strain SCS110-AF/VTvaf17-KRT14, or Escherichia coli strain SCS110-AF/VTvaf17-LAMB3, or Escherichia coli strain SCS110-AF/VTvaf17-COL7A1 carrying the gene therapy DNA vector, mCELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
- 0538US2024060083A1Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, methodCELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
- 0638US2024325569A1Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-BDNF, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-BFGF, or Escherichia coli strain SCS110-AF/VTvaf17-NGF, or Escherichia coli strCELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
- 0737US2024269324A1Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of ANG, ANGPT1, VEGFA, FGF1, HIF1a, HGF, SDF1, KLK4, PDGFC, PROK1, and PROK2 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-ANG, or Escherichia coli strain SCS110-AF/VTvaf17-ANGPT1, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-FGFCELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
- 0837US2024366787A1Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/VCELL and GENE THERAPY Ltd·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CELL and GENE THERAPY Ltd files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →